Growthpoint exec deferred scheme options vest in R5.31 million transaction
Bitget2026/10/09 06:20Growthpoint disclosed dealings by major subsidiary director F Schindehütte involving 339,583 ordinary shares from vested deferred and retention scheme options. He sold 153,692 shares at a volume-weighted average price of R15.4714, raising R2.38 million to fund tax. He retained 185,891 shares; the vesting and exercise used a deemed price of R15.63, valuing the transaction at R5.31 million. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Growthpoint Properties Limited published the original content used to generate this news brief via SENS, the regulatory disclosure system operated by the Johannesburg Securities Exchange (JSE) (Ref. ID: S604664), on October 09, 2026, and is solely responsible for the information contained therein.
- Growthpoint disclosed dealings by major subsidiary director F Schindehütte involving 339,583 ordinary shares from vested deferred and retention scheme options.
- He sold 153,692 shares at a volume-weighted average price of R15.4714, raising R2.38 million to fund tax.
- He retained 185,891 shares; the vesting and exercise used a deemed price of R15.63, valuing the transaction at R5.31 million.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canaccord Genuity: Lowers Oklo's target price to $66
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
Crypto prices
More
